GE Healthcare Release: CHMP Recommends EU Approval Of VIZAMYL™ (Flutemetamol F18 Injection) For PET Imaging Of Beta Amyloid Plaque

Published: Jun 30, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CHALFONT ST. GILES, England--(BUSINESS WIRE)--GE Healthcare today announced the receipt of a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). This opinion recommends the granting of a marketing authorisation for VIZAMYL™ (Flutemetamol F18 injection), a radiopharmaceutical medicinal product indicated for Positron Emission Tomography (PET) imaging of beta amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. VIZAMYL™ is for diagnostic use only and should be used in conjunction with a clinical evaluation.

Help employers find you! Check out all the jobs and post your resume.

Back to news